• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
OPT

OPTHEA LIMITED - Corporate Spotlight

0.00% ! 60.0¢
Market Cap $738.7M  !
Healthcare Biotechnology
Add to My Watchlist

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The... Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
60.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $738.7M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0
OPT (ASX) Chart

Top Stories

Can the market squeeze IDP Education's shorters? As of Week 33, it looks possible

IDP Education (ASX:IEL), a company that ultimately trains up foreign students moving to Australia, has long been one of the most...
The cash flow on demand strategy that works This week on Money and Investing, Mitch Olarenshaw and I break down the strategy behind Cash Flow on Demand @ a proven system for generating consistent income from the sharemarket with lower risk.1. The cash flow on demand strategyThis income strategy has been our flagship approach at Australian ...
Trump's not talking about Greenland – so why is ETM up +130%? Sixty Minutes is, in many ways, peak boomer. The not-so-shiny-anymore crown jewel of a media brand now more invested in property...
DroneShield's civilian counter-drone tech lands with a buzz A silent guardian, standing tall and watching the skies. No, it’s not a superhero, but DroneShield’s (ASX:DRO) newest brainchild, SentryCiv: A new subscription-based counter-drone system for the civilian market.Listen to the HotCopper podcast for in-depth discussio...
Monday's HotCopper trends: DRO civ counterdrone, Dateline drill hits | Aug 11 DroneShield (ASX:DRO) has captured the most attention across the HotCopper forums through Week 33’s first trade day, sparking excitement with its new @SentryCiv,” a subscription-based AI counterdrone solution.Listen to the HotCopper podcast for in-depth discu...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.